Blase Polite
Medical Oncology · Chicago, ILNPI 1306873211
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,495 of the $6,682 with a category attached, or 82.2%. Sanofi accounts for 82.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $5,613 and has fallen 98.0% since, to $115 in 2025.
Across 15 payments — averaging $445.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$5K
- AstraZeneca$377
- Bayer$285
- Lilly USA, LLC$162
- Exelixis Inc.$136
- Merck$114
- plus $113 from 1 others
Across 89 payments — averaging $14,056 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
- Array Biopharma Inc$45K
- Novartis$16K
- Pfizer$10K
What the payments were for
- Consulting fees$5,49582%
- Food & beverage$1,18718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $5,495 |
| AstraZeneca | 4 | $377 |
| Bayer | 3 | $285 |
| Lilly USA, LLC | 3 | $162 |
| Exelixis Inc. | 2 | $136 |
| Merck | 1 | $114 |
| Genentech USA, Inc. | 1 | $113 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,682 in reported general payments places this provider in the 70th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 12 | $635 |
| Duloxetine Hcl | 28 | $350 |
| Ondansetron Hcl | 17 | $288 |
| Doxycycline Hyclate | 11 | $282 |
| Pantoprazole Sodium | 13 | $259 |
| Prochlorperazine Maleate | 14 | $184 |
| Dexamethasone | 12 | $158 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $17 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Chicago
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Jyoti PatelChicago$175K
- Al BensonChicago$163K
- Nisha MohindraChicago$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.